BRAF and melanoma: BRAFinhibition has been demonstrated to be an effective therapeutic target in melanoma; dabrafenib joinsvemurafenib, an oral BRAF inhibitor, which was FDA approved in 2011 (Tawbi & Kirkwood, 2012).